Emerging classes of protein-protein interaction inhibitors and new tools for their development

Current Opinion in Chemical Biology

Volumn 8, Issue 4, 2004, Pages 442-449

  Pagliaro, Len ^a   Felding, Jakob ^a   Audouze, Karine ^a   Nielsen, Søren Jensby ^a   Terry, Robert B ^a   Krog Jensen, Christian ^a   Butcher, Steven ^a  

^a BioImage AS   (Denmark)

Author keywords

inducible nitric oxide synthase; iNOS; MoA; mode of action; PCA; phosphatidylinositol 3 kinase; phosphatidylinositol 3,4,5 triphosphate; PI3K; PIP3; principal component analysis; small molecule protein protein interaction inhibitor; SMPPII

Indexed keywords

INSULIN; PROTEIN INHIBITOR; SMALL MOLECULE PROTEIN PROTEIN INTERACTION INHIBITOR; UNCLASSIFIED DRUG;

DRUG DESIGN; DRUG TARGETING; INHIBITION KINETICS; INSULIN BINDING; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; COMPUTATIONAL BIOLOGY; DRUG DESIGN; HUMANS; MODELS, BIOLOGICAL; MODELS, MOLECULAR; MOLECULAR STRUCTURE; PROTEIN BINDING; PROTEINS; SIGNAL TRANSDUCTION;

EID: 3342908718     PISSN: 13675931     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cbpa.2004.06.006     Document Type: Review

References (54)

1. Marcotte E.M., Pellegrini M., Ng H.L., Rice D.W., Yeates T.O., Eisenberg D. Detecting protein function and protein-protein interactions from genome sequences. Science. 285:1999;751-753
2. Juliano R.L., Astriab-Fisher A., Falke D. Macromolecular therapeutics: emerging strategies for drug discovery in the postgenome era. Mol Interv. 1:2001;40-53
3. DeLano W.L. Unraveling hot spots in binding interfaces: progress and challenges. Curr Opin Struct Biol. 12:2002;14-20
4. Fernandez A., Scott R. Dehydron: a structurally encoded signal for protein interaction. Biophys J. 85:2003;1914-1928
5. Archakov A.I., Govorun V.M., Dubanov A.V., Ivanov Y.D., Veselovsky A.V., Lewi P., Janssen P. Protein-protein interactions as a target for drugs in proteomics. Proteomics. 3:2003;380-391
6. Teruel M.N., Meyer T. Translocation and reversible localization of signaling proteins: a dynamic future for signal transduction. Cell. 103:2000;181-184
7. Jordan J.D., Landau E.M., Iyengar R. Signaling networks: the origins of cellular multitasking. Cell. 103:2000;193-200
8. Toogood P.L. Inhibition of protein-protein association by small molecules: approaches and progress. J Med Chem. 45:2002;1543-1558
9. Berg T. Modulation of protein-protein interactions with small organic molecules. Angew Chem Int Ed Engl. 42:2003;2462-2481 An excellent review summarizing the different approaches used to identify small-molecule protein-protein modulators.
10. Kau T.R., Silver P.A. Nuclear transport as a target for cell growth. Drug Discov Today. 8:2003;78-85
11. Lu Y., Wang H., Mills G.B. Targeting the PI3K-AKT pathway for cancer therapy. Rev Clin Exp Hematol. 7:2003;205-228
12. Boger D.L., Desharnais J., Capps K. Solution-phase combinatorial libraries: modulating cellular signaling by targeting protein-protein or protein-DNA interactions. Angew Chem Int Ed Engl. 42:2003;4138-4176
13. Ernst J.T., Becerril J., Park H.S., Yin H., Hamilton A.D. Design and application of an alpha-helix-mimetic scaffold based on an oligoamide-foldamer strategy: antagonism of the Bak BH3/Bcl-xL complex. Angew Chem Int Ed Engl. 42:2003;535-539
14. Degterev A., Lugovskoy A., Cardone M., Mulley B., Wagner G., Mitchison T., Yuan J. Identification of small-molecule inhibitors of interaction between the BH3 domain and Bcl-xL. Nat Cell Biol. 3:2001;173-182
15. Lepourcelet M., Chen Y.N., France D.S., Wang H., Crews P., Petersen F., Bruseo C., Wood A.W., Shivdasani R.A. Small-molecule antagonists of the oncogenic Tcf/beta-catenin protein complex. Cancer Cell. 5:2004;91-102 A study in which both a 7000-member natural product library and a 45 000 member synthetic small-molecule library were screened against a protein-protein interaction library. The only inhibitors identified in this study were from the natural product library, whereas the synthetic compound library failed to provide additional hits. This study underscores the importance of screening the appropriate chemistry, whatever the assay technology.
16. Gadek T.R., Burdick D.J., McDowell R.S., Stanley M.S., Marsters J.C. Jr., Paris K.J., Oare D.A., Reynolds M.E., Ladner C., Zioncheck K.A., et al. Generation of an LFA-1 antagonist by the transfer of the ICAM-1 immunoregulatory epitope to a small molecule. Science. 295:2002;1086-1089
17. Winn M., Reilly E.B., Liu G., Huth J.R., Jae H.S., Freeman J., Pei Z., Xin Z., Lynch J., Kester J., von Geldern T.W., Leitza S., DeVries P., Dickinson R., Mussatto D., Okasinski G.F. Discovery of novel p-arylthio cinnamides as antagonists of leukocyte function-associated antigen-1/intercellular adhesion molecule-1 interaction. 4. Structure-activity relationship of substituents on the benzene ring of the cinnamide. J Med Chem. 44:2001;4393-4403
18. Kelly T.A., Jeanfavre D.D., McNeil D.W., Woska J.R. Jr., Reilly P.L., Mainolfi E.A., Kishimoto K.M., Nabozny G.H., Zinter R., Bormann B.J., Rothlein R. Cutting edge: a small molecule antagonist of LFA-1-mediated cell adhesion. J Immunol. 163:1999;5173-5177
19. Last-Barney K., Davidson W., Cardozo M., Frye L.L., Grygon C.A., Hopkins J.L., Jeanfavre D.D., Pav S., Qian C., Stevenson J.M., Tong L., Zindell R., Kelly T.A. Binding site elucidation of hydantoin-based antagonists of LFA-1 using multidisciplinary technologies: evidence for the allosteric inhibition of a protein-protein interaction. J Am Chem Soc. 123:2001;5643-5650
20. Daelemans D., Afonina E., Nilsson J., Werner G., Kjems J., De Clercq E., Pavlakis G.N., Vandamme A.M. A synthetic HIV-1 Rev inhibitor interfering with the CRM1-mediated nuclear export. Proc Natl Acad Sci USA. 99:2002;14440-14445
21. Sarabu R., Cooper J.P., Cook C.M., Gillespie P., Perrotta A.V., Olson G.L. Design and synthesis of small molecule interleukin-1 receptor antagonists based on a benzene template. Drug Des Discov. 15:1997;191-198
22. Qureshi S.A., Kim R.M., Konteatis Z., Biazzo D.E., Motamedi H., Rodrigues R., Boice J.A., Calaycay J.R., Bednarek M.A., Griffin P., Gao Y.D., Chapman K., Mark D.F. Mimicry of erythropoietin by a nonpeptide molecule. Proc Natl Acad Sci USA. 96:1999;12156-12161
23. Baba M., Nishimura O., Kanzaki N., Okamoto M., Sawada H., Iizawa Y., Shiraishi M., Aramaki Y., Okonogi K., Ogawa Y., Meguro K., Fujino M. A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity. Proc Natl Acad Sci USA. 96:1999;5698-5703
24. Owolabi J.B., Rizkalla G., Tehim A., Ross G.M., Riopelle R.J., Kamboj R., Ossipov M., Bian D., Wegert S., Porreca F., Lee D.K. Characterization of antiallodynic actions of ALE-0540, a novel nerve growth factor receptor antagonist, in the rat. J Pharmacol Exp Ther. 289:1999;1271-1276
25. Wang J.L., Liu D., Zhang Z.J., Shan S., Han X., Srinivasula S.M., Croce C.M., Alnemri E.S., Huang Z. Structure-based discovery of an organic compound that binds Bcl-2 protein and induces apoptosis of tumor cells. Proc Natl Acad Sci USA. 97:2000;7124-7129
26. An J, Chen Y, Huang Z: Critical upstream signals of cytochrome c release induced by a novel Bcl-2 inhibitor. J Biol Chem 2004 Feb 13 (in press).
27. Enyedy I.J., Ling Y., Nacro K., Tomita Y., Wu X., Cao Y., Guo R., Li B., Zhu X., Huang Y., Long Y.Q., Roller P.P., Yang D., Wang S. Discovery of small-molecule inhibitors of Bcl-2 through structure-based computer screening. J Med Chem. 44:2001;4313-4324
28. Braisted A.C., Oslob J.D., Delano W.L., Hyde J., McDowell R.S., Waal N., Yu C., Arkin M.R., Raimundo B.C. Discovery of a potent small molecule IL-2 inhibitor through fragment assembly. J Am Chem Soc. 125:2003;3714-3715
29. Stoll R., Renner C., Hansen S., Palme S., Klein C., Belling A., Zeslawski W., Kamionka M., Rehm T., Muhlhahn P., et al. Chalcone derivatives antagonize interactions between the human oncoprotein MDM2 and p53. Biochemistry. 40:2001;336-344
30. Vassilev L.T., Vu B.T., Graves B., Carvajal D., Podlaski F., Filipovic Z., Kong N., Kammlott U., Lukacs C., Klein C., et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science. 303:2004;844-848 Identification of SMPPIIs with therapeutic potential using a structural biological approach in a pharmaceutical industrial setting.
31. Edling A.E., Choksi S., Huang Z., Korngold R. An organic CD4 inhibitor reduces the clinical and pathological symptoms of acute experimental allergic encephalomyelitis. J Autoimmun. 18:2002;169-179
32. Berg T., Cohen S.B., Desharnais J., Sonderegger C., Maslyar D.J., Goldberg J., Boger D.L., Vogt P.K. Small-molecule antagonists of Myc/Max dimerization inhibit Myc-induced transformation of chicken embryo fibroblasts. Proc Natl Acad Sci USA. 99:2002;3830-3835
33. Chene P. Inhibition of the p53-MDM2 interaction: targeting a protein-protein interface. Mol Cancer Res. 2:2004;20-28
34. Lukacs C, Kammlott U, Graves B: Crystal structure of human MDM2 with an imidazoline inhibitor. Protein Data Bank, 2004.
35. Xu J., Stevenson J. Drug-like Index: A New Approach to Measure Drug-like Compounds and Their Diversity. J Chem Inf Comput Sci. 40:2000;1177-1187
36. Lipinski C.A., Lombardo F., Dominy B.W., Feeney P.J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev. 46:2001;3-26
37. Rodriguez A.L., Tamrazi A., Collins M.L., Katzenellenbogen J.A. Design, synthesis, and in vitro biological evaluation of small molecule inhibitors of estrogen receptor alpha coactivator binding. J Med Chem. 47:2004;600-611 An example in which SMPPIIs effective against estrogen receptor via a novel mode of action were developed using a rational design chemistry approach. Rather than antagonizing estrogen receptor directly, this study describes SMPPIIs that inhibit binding of co-activator to the receptor. In the absence of co-activator, the receptor lacks activity.
38. Schreiber S.L. The small-molecule approach to biology: Chemical genetics and diversity-oriented organic synthesis make possible the systematic exploration of biology. Chem Eng News. 81:2003;51-61
39. Burke M.D., Schreiber S.L. A planning strategy for diversity-oriented synthesis. Angew Chem Int Ed Engl. 43:2004;46-58
40. Almholt K., Arkhammar P.O., Thastrup O., Tullin S. Simultaneous visualization of the translocation of protein kinase C alpha-green fluorescent protein hybrids and intracellular calcium concentrations. Biochem J. 337:1999;211-218
41. Terry R., Cheung Y.-F., Præstegaard M., Baillie G.S., Huston E., Gall I., Adams D.R., Houslay M.D. Occupancy of the catalytic site of the PDE4A4 cyclic AMP phosphodiesterase by rolipram triggers the dynamic redistribution of this specific isoform in living cells tthrough a cyclic AMP independent process. Cell Signal. 15:2003;955-971
42. ® screen. Assay Drug Dev Technol. 2:2004;7-20 Hits with several modes of action in the p38-MAP kinase pathway were discovered in a high content cell-based translocation assay screen.
43. Lundholt BK, Linde, Loechel S, Pedersen HC, Møller S, Præstegaard M, Scudder K, Bjørn SP, Heide M, Arknammar POG, Terry R, Nielsen SJ: Identification of Akt pathway inhibitors using Redistribution® screening on the FLIPR and the IN Cell 3000 Analyzer. J Biomol Screen 2004, 9: in press.
44. Kau T.R., Schroeder F., Ramaswamy S., Wojciechowski C.L., Zhao J.J., Roberts T.M., Clardy J., Sellers W.R., Silver P.A. A chemical genetic screen identifies inhibitors of regulated nuclear export of a Forkhead transcription factor in PTEN-deficient tumor cells. Cancer Cell. 4:2003;463-476
45. ® assay using a cAMP-dependent protein kinase-green fluorescent protein chimera. Cell Signal. 16:2004;907-920
46. Ferguson S.S., Caron M.G. Green fluorescent protein-tagged beta-arrestin translocation as a measure of G protein-coupled receptor activation. Methods Mol Biol. 237:2004;121-126
47. Kaihara A., Kawai Y., Sato M., Ozawa T., Umezawa Y. Locating a protein-protein interaction in living cells via split Renilla luciferase complementation. Anal Chem. 75:2003;4176-4181
48. Yu H., West M., Keon B.H., Bilter G.K., Owens S., Lamerdin J., Westwick J.K. Measuring drug action in the cellular context using protein-fragment complementation assays. Assay Drug Dev Technol. 1:2003;811-822
49. McMillan K., Adler M., Auld D.S., Baldwin J.J., Blasko E., Browne L.J., Chelsky D., Davey D., Dolle R.E., Eagen K.A., et al. Allosteric inhibitors of inducible nitric oxide synthase dimerization discovered via combinatorial chemistry. Proc Natl Acad Sci USA. 97:2000;1506-1511
50. Blasko E., Glaser C.B., Devlin J.J., Xia W., Feldman R.I., Polokoff M.A., Phillips G.B., Whitlow M., Auld D.S., McMillan K., et al. Mechanistic studies with potent and selective inducible nitric-oxide synthase dimerization inhibitors. J Biol Chem. 277:2002;295-302 An illustration of the advantages of cell-based assays for primary screening. A library screened against a cell-based iNOS assay identified potent, progressable hits not identified in a screen of the same compounds against a catalytic activity assay based on active, partially purified iNOS holo-enzyme. Functional iNOS is a dimer, and the hits identified only in the cell-based assay effectively inhibit dimerization - and thus activity.
51. Erlanson D.A., McDowell R.S., O'Brien T. Fragment-based drug discovery. J Med Chem. 47:2004;1-20
52. Arkin M.R., Wells J.A. Small-molecule inhibitors of protein-protein interactions: progressing towards the dream. Nat Rev Drug Disc. 3:2004;301-317
53. Gao Y., Dickerson J.B., Guo F., Zheng J., Zheng Y. Rational design and characterizaton of a Rac GTPase-specific small molecule inhibitor. Proc Natl Acad Sci USA. 101:2004;7618-7623
54. Roehrl M.H.A., Kang S., Aramburu J., Wagner G., Rao A., Hogan P.G. Selective inhibition of calcineurin-NFAT signaling by blocking protein-protein interaction with small organic molecules. Proc Natl Acad Sci USA. 101:2004;7554-7559